Get started
Work

Impact of COVID-19 on Heart Failure Clinical Trials

Year: 2023
Type: article
DOI: 10.1016/j.jchf.2022.11.024
Authors: Ankeet S. Bhatt, Matthew Dimond, Mona Fiuzat, Muthiah Vaduganathan, Orly Vardeny, Punag Divanji, Jan Komtebedde, Martin P. Lefkowitz, Richard Nkulikiyinka, Magnus Petersson, Lothar Roessig, Daniel Schaber, Christopher M. O’Connor, Scott D. Solomon
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, AstraZeneca, Bayer, GlaxoSmithKline, Sanofi, Gilead Sciences, Alnylam Pharmaceuticals, Celladon Corporation, Cytokinetics, Sarepta Therapeutics, MyoKardia, Impulse Dynamics, Moderna, Abiomed, Novo Nordisk, National Institutes of Health, U.S. Food and Drug Administration, Sanofi Pasteur, American Regent, Respicardia, Relypsa, National Institute on Aging, National Heart, Lung, and Blood Institute, Daiichi Sankyo Europe
Awards: Multimorbidity and Aging: Rochester Epidemiology Project, G3029506724, G4054004451, G4090225628, G6078766973, G72586386, Advanced Heart Failure: Epidemiology and Outcomes, G9000172197, Training Grant in Cardiovascular Research
OpenAlex ID: W4319303302
FWCI: 0.61
Cites: 2
Cited by: 5
Related to: 10